Corient Private Wealth LP Makes New $2.19 Million Investment in Sana Biotechnology, Inc. $SANA

by · The Markets Daily

Corient Private Wealth LP purchased a new position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA – Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 628,200 shares of the company’s stock, valued at approximately $2,192,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Bank of America Corp DE acquired a new stake in shares of Sana Biotechnology in the 2nd quarter worth $20,062,000. Jupiter Topco LLC acquired a new position in Sana Biotechnology during the 2nd quarter valued at about $202,000. Hsbc Holdings PLC acquired a new position in Sana Biotechnology during the 2nd quarter valued at about $392,000. Canada Pension Plan Investment Board purchased a new stake in Sana Biotechnology in the second quarter valued at about $35,662,000. Finally, Legal & General Group Plc purchased a new stake in Sana Biotechnology in the second quarter valued at about $475,000. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on SANA shares. Weiss Ratings upgraded Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 23rd. Wall Street Zen lowered shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a research report on Monday, July 20th. Bank of America dropped their target price on shares of Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. TD Cowen upgraded shares of Sana Biotechnology to a “strong-buy” rating in a research note on Monday, August 24th. Finally, Rodman & Renshaw began coverage on shares of Sana Biotechnology in a research note on Monday, May 11th. They set a “buy” rating and a $16.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $9.33.

View Our Latest Report on SANA

Sana Biotechnology Stock Up 1.6%

Sana Biotechnology stock opened at $3.89 on Thursday. The stock has a 50-day moving average price of $3.60 and a 200 day moving average price of $3.41. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of -5.12 and a beta of 2.12. Sana Biotechnology, Inc. has a 52 week low of $2.61 and a 52 week high of $6.55.

Sana Biotechnology (NASDAQ:SANA – Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.02. Research analysts anticipate that Sana Biotechnology, Inc. will post -0.72 EPS for the current fiscal year.

About Sana Biotechnology

(Free Report)

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.

Read More

Want to see what other hedge funds are holding SANA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sana Biotechnology, Inc. (NASDAQ:SANA – Free Report).